Blood metabolites as predictors of skin cancer risk: a comprehensive analysis
19 ago 2024
Acerca de este artículo
Categoría del artículo: Original Study
Publicado en línea: 19 ago 2024
Páginas: 74 - 85
Recibido: 14 feb 2024
Aceptado: 19 jun 2024
DOI: https://doi.org/10.2478/ahem-2004-0007
Palabras clave
© 2024 Kaymin Wu et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1.

Figure 2.

Figure S1.

Metabolites with significant pleiotropy
X-12117 | Egger Intercept | 0.043 |
X-13695 | Egger Intercept | 0.049 |
Oleoyl-linoleoyl-glycerol (18:1 to 18:2) [2] / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [2] | Egger Intercept | 0.024 |
Adenosine 5′-diphosphate (ADP) / cytidine | Egger Intercept | 0.025 |
Caffeine / linoleate (18:2n6) | Egger Intercept | 0.047 |
Gamma-glutamylthreonine | Global Test | <0.001 |
Picolinoylglycine | Global Test | <0.001 |
Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) | Global Test | 0.012 |
Cysteinylglycine | Global Test | 0.017 |
Hypotaurine | Global Test | 0.011 |
Cortisone / 4-cholesten-3-one | Global Test | 0.029 |
Hypotaurine / cysteine | Global Test | 0.003 |
Retinol (Vitamin A) / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [2] | Global Test | 0.011 |
Plasma metabolites significantly associated with skin cancer
GCST90199649 | 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) | 0,00051977 |
GCST90199652 | 1-stearoyl-2-oleoyl-GPS (18:0/18:1) | 0,02555615 |
GCST90199664 | Phenyllactate (PLA) | 0,01272859 |
GCST90199681 | 2-hydroxyoctanoate | 0,00388752 |
GCST90199704 | 3-hydroxysebacate | 0,02108698 |
GCST90199749 | Gamma-glutamylthreonine | 0,01482424 |
GCST90199770 | 1-arachidonylglycerol (20:4) | 0,00037937 |
GCST90199790 | 2-palmitoleoyl-GPC (16:1) | 0,00713541 |
GCST90199794 | 1-oleoyl-GPE (18:1) | 0,0064445 |
GCST90199816 | 3,4-dihydroxybutyrate | 0,0457161 |
GCST90199828 | N-acetylserine | 0,03545266 |
GCST90199861 | Pregnenediol sulfate (C21H34O5S) | 0,00620384 |
GCST90199875 | 13-HODE + 9-HODE | 0,02436659 |
GCST90199879 | Ergothioneine | 0,0122909 |
GCST90199883 | Cysteinylglycine disulfide | 0,04409296 |
GCST90199899 | 1-(1-enyl-palmitoyl)-GPC (p-16:0) | 0,04371435 |
GCST90199901 | 1-methyl-5-imidazoleacetate | 0,02084982 |
GCST90199910 | 1-(1-enyl-stearoyl)-GPE (p-18:0) | 0,03700612 |
GCST90199936 | 3-methyl catechol sulfate (2) | 0,00225296 |
GCST90199952 | 2-aminoheptanoate | 0,0471971 |
GCST90199986 | Eugenol sulfate | 0,02831923 |
GCST90200028 | 1-stearoyl-2-oleoyl-gpc (18:0/18:1) | 0,03353492 |
GCST90200030 | 1,2-dilinoleoyl-GPC (18:2/18:2) | 0,04356157 |
GCST90200037 | 1-stearoyl-2-linoleoyl-gpc (18:0/18:2) | 0,02938405 |
GCST90200041 | 1-palmitoyl-2-stearoyl-gpc (16:0/18:0) | 0,04687286 |
GCST90200046 | 1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) | 0,00835308 |
GCST90200051 | 1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) | 0,04290723 |
GCST90200102 | 1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) | 0,01098387 |
GCST90200104 | Hexadecadienoate (16:2n6) | 0,02519585 |
GCST90200161 | 2-hydroxyarachidate | 0,02755643 |
GCST90200222 | Dihydrocaffeate sulfate (2) | 0,00510208 |
GCST90200234 | Picolinoylglycine | 0,0205488 |
GCST90200243 | Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) | 0,04697794 |
GCST90200316 | N-acetylglucosaminylasparagine | 0,03549567 |
GCST90200319 | Cys-gly, oxidized | 0,00216651 |
GCST90200320 | Dihomo-linoleate (20:2n6) | 0,00119897 |
GCST90200364 | Cysteinylglycine | 0,01360229 |
GCST90200379 | Hypotaurine | 0,03014081 |
GCST90200394 | Inosine | 0,00761015 |
GCST90200447 | Maltose | 0,04370196 |
GCST90200452 | Plasma free asparagine | 0,03560774 |
GCST90200462 | X-11299 | 0,01505161 |
GCST90200474 | X-11444 | 0,04987119 |
GCST90200488 | X-12117 | 0,02906436 |
GCST90200524 | X-13695 | 0,00992943 |
GCST90200526 | X-14056 | 0,00904827 |
GCST90200547 | X-17654 | 0,03591522 |
GCST90200596 | X-23655 | 0,01764105 |
GCST90200601 | X-23654 | 0,01063422 |
GCST90200614 | X-23780 | 0,00499579 |
GCST90200672 | X-26054 | 0,03080663 |
GCST90200696 | N6,N6-dimethyllysine | 0,03796103 |
GCST90200708 | X-12112 | 0,00021692 |
GCST90200710 | X-13431 | 0,02265676 |
GCST90200711 | X-19141 | 0,03481623 |
GCST90200717 | 3-phosphoglycerate / adenosine 5′-diphosphate (ADP) | 0,01479885 |
GCST90200731 | Adenosine 5′-diphosphate (ADP) / mannose | 0,03623322 |
GCST90200733 | Adenosine 5′-diphosphate (ADP) / N-acetylglucosamine / N-acetylgalactosamine | 0,03158844 |
GCST90200739 | Adenosine 5′-monophosphate (AMP) / proline | 0,0480536 |
GCST90200749 | Arachidonate (20:4n6) / pyruvate | 0,03241957 |
GCST90200795 | Oleoyl-linoleoyl-glycerol (18:1 to 18:2) [2] / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [2] | 0,0450439 |
GCST90200876 | Cortisone / 4-cholesten-3-one | 0,01656538 |
GCST90200884 | Mannose / N-acetylglucosamine / N-acetylgalactosamine ratio | 0,00172666 |
GCST90200886 | Phenylpyruvate / 4-hydroxyphenylpyruvate | 0,04604498 |
GCST90200895 | Hypotaurine / cysteine | 0,00096089 |
GCST90200904 | Phosphate / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [1] | 0,01887088 |
GCST90200908 | Retinol (Vitamin A) / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [2] | 0,04377634 |
GCST90200913 | Glucose / sucrose | 0,03063799 |
GCST90200919 | Caffeine / theophylline | 0,023528 |
GCST90200934 | Acetylcarnitine (C2) / propionylcarnitine (C3) | 0,02407541 |
GCST90200952 | Adenosine 5′-diphosphate (ADP) / cytidine | 0,03408387 |
GCST90200956 | Cytidine / N-acetylglucosamine / N-acetylgalactosamine ratio | 0,031094 |
GCST90200963 | Inosine 5′-monophosphate (IMP) / urate | 0,04239604 |
GCST90200971 | Leucine / phosphate | 0,00364409 |
GCST90200979 | Arachidonate (20:4n6) / linoleate (18:2n6) | 0,0003571 |
GCST90200981 | Caffeine / linoleate (18:2n6) | 0,04354453 |
GCST90200983 | Cholesterol / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [1] | 0,01367908 |
GCST90200992 | Alanine / asparagine | 0,02078138 |
Plasma metabolites increase and decrease skin cancer risk
Caffeine / linoleate (18:2n6) | Inverse variance weighted | 13 | 0,043545 | 1,076646 | 1,002141 | 1,15669 |
Arachidonate (20:4n6) / pyruvate | Inverse variance weighted | 14 | 0,03242 | 1,065368 | 1,005318 | 1,129004 |
X-13695 | Inverse variance weighted | 16 | 0,009929 | 1,075629 | 1,017637 | 1,136926 |
Hexadecadienoate (16:2n6) | Inverse variance weighted | 17 | 0,025196 | 1,097468 | 1,011634 | 1,190584 |
Cysteinylglycine disulfide | Inverse variance weighted | 18 | 0,044093 | 1,060359 | 1,00155 | 1,122622 |
X-14056 | Inverse variance weighted | 18 | 0,009048 | 1,063733 | 1,01551 | 1,114245 |
Adenosine 5′-diphosphate (ADP) / cytidine | Inverse variance weighted | 18 | 0,034084 | 1,061076 | 1,00446 | 1,120882 |
1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels | Inverse variance weighted | 19 | 0,025556 | 1,080005 | 1,009451 | 1,15549 |
Cysteinylglycine | Inverse variance weighted | 19 | 0,013602 | 1,09644 | 1,019119 | 1,179626 |
13-HODE + 9-HODE | Inverse variance weighted | 20 | 0,024367 | 1,082627 | 1,010325 | 1,160103 |
Maltose | Inverse variance weighted | 20 | 0,043702 | 1,062032 | 1,0017 | 1,125997 |
X-11299 | Inverse variance weighted | 20 | 0,015052 | 1,073446 | 1,01383 | 1,136568 |
Adenosine 5′-monophosphate (AMP) / proline | Inverse variance weighted | 20 | 0,048054 | 1,069258 | 1,000572 | 1,142658 |
2-hydroxyoctanoate | Inverse variance weighted | 21 | 0,003888 | 1,070316 | 1,022062 | 1,120849 |
3-hydroxysebacate | Inverse variance weighted | 21 | 0,021087 | 1,069122 | 1,01009 | 1,131605 |
1-arachidonylglycerol (20:4) | Inverse variance weighted | 22 | 0,000379 | 1,094837 | 1,041475 | 1,150933 |
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) | Inverse variance weighted | 23 | 0,00052 | 1,083601 | 1,035561 | 1,13387 |
Leucine / phosphate | Inverse variance weighted | 23 | 0,003644 | 1,102396 | 1,032277 | 1,177277 |
N-acetylserine | Inverse variance weighted | 24 | 0,035453 | 1,079408 | 1,005215 | 1,159077 |
1-(1-enyl-stearoyl)-GPE (p-18:0) | Inverse variance weighted | 24 | 0,037006 | 1,053769 | 1,003161 | 1,106929 |
Cys-gly, oxidized | Inverse variance weighted | 24 | 0,002167 | 1,076121 | 1,026824 | 1,127786 |
N6,N6-dimethyllysine | Inverse variance weighted | 24 | 0,037961 | 1,033057 | 1,001808 | 1,06528 |
Arachidonate (20:4n6) / linoleate (18:2n6) | Inverse variance weighted | 24 | 0,000357 | 1,075175 | 1,033228 | 1,118825 |
2-palmitoleoyl-GPC (16:1) | Inverse variance weighted | 25 | 0,007135 | 1,076291 | 1,020161 | 1,135508 |
1-(1-enyl-palmitoyl)-GPC (p-16:0) | Inverse variance weighted | 25 | 0,043714 | 1,057154 | 1,001567 | 1,115827 |
3-methyl catechol sulfate (2) | Inverse variance weighted | 25 | 0,002253 | 1,068963 | 1,024187 | 1,115697 |
Phenyllactate (PLA) | Inverse variance weighted | 26 | 0,012729 | 1,078143 | 1,016175 | 1,143889 |
1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) | Inverse variance weighted | 27 | 0,008353 | 1,064194 | 1,01611 | 1,114554 |
X-11444 | Inverse variance weighted | 27 | 0,049871 | 1,047225 | 1,000025 | 1,096652 |
Phenylpyruvate / 4-hydroxyphenylpyruvate | Inverse variance weighted | 27 | 0,046045 | 1,061408 | 1,001046 | 1,125409 |
1-oleoyl-GPE (18:1) | Inverse variance weighted | 28 | 0,006444 | 1,078553 | 1,021441 | 1,138858 |
Hypotaurine | Inverse variance weighted | 28 | 0,030141 | 1,072348 | 1,006731 | 1,142242 |
X-17654 | Inverse variance weighted | 28 | 0,035915 | 1,042319 | 1,002728 | 1,083474 |
1-palmitoyl-2-stearoyl-gpc (16:0/18:0) | Inverse variance weighted | 29 | 0,046873 | 1,054884 | 1,000738 | 1,111959 |
Dihydrocaffeate sulfate (2) | Inverse variance weighted | 29 | 0,005102 | 1,075662 | 1,022132 | 1,131995 |
X-26054 | Inverse variance weighted | 30 | 0,030807 | 1,038238 | 1,003474 | 1,074207 |
Alanine / asparagine | Inverse variance weighted | 31 | 0,020781 | 1,046554 | 1,006951 | 1,087715 |
X-12117 | Inverse variance weighted | 32 | 0,029064 | 1,043675 | 1,00437 | 1,084519 |
1-stearoyl-2-oleoyl-gpc (18:0/18:1) | Inverse variance weighted | 33 | 0,033535 | 1,068588 | 1,005182 | 1,135993 |
Hypotaurine / cysteine | Inverse variance weighted | 33 | 0,000961 | 1,1238 | 1,048573 | 1,204424 |
X-12112 | Inverse variance weighted | 35 | 0,000217 | 1,054967 | 1,025471 | 1,085311 |
X-23654 | Inverse variance weighted | 38 | 0,010634 | 1,058993 | 1,013429 | 1,106605 |
Metabolites with significant heterogeneity (MR Egger or Inverse variance weighted)
Metabolites | Method | Q | Q_df | Q_pval |
---|---|---|---|---|
1-stearoyl-2-oleoyl-gpc (18:0/18:1) | MR Egger | 45.43 | 31 | 0.045
|
1-stearoyl-2-oleoyl-gpc (18:0/18:1) | Inverse variance weighted | 45.62 | 32 | 0.056 |
2-hydroxyarachidate | MR Egger | 39.57 | 20 | 0.006 |
2-hydroxyarachidate | Inverse variance weighted | 47.17 | 21 | 0.001 |
Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) | MR Egger | 48.40 | 29 | 0.013 |
Hydroxypalmitoyl sphingomyelin (d18:1/16:0(OH)) | Inverse variance weighted | 48.54 | 30 | 0.017 |
Cysteinylglycine | MR Egger | 31.72 | 17 | 0.016 |
Cysteinylglycine | Inverse variance weighted | 34.74 | 18 | 0.01 |
Hypotaurine | MR Egger | 45.67 | 26 | 0.01 |
Hypotaurine | Inverse variance weighted | 45.74 | 27 | 0.013 |
X-13431 | MR Egger | 39.43 | 25 | 0.033 |
X-13431 | Inverse variance weighted | 39.52 | 26 | 0.043 |
Cortisone / 4-cholesten-3-one | MR Egger | 39.82 | 29 | 0.087 |
Cortisone / 4-cholesten-3-one | Inverse variance weighted | 43.83 | 30 | 0.049 |
Hypotaurine / cysteine | MR Egger | 54.17 | 31 | 0.006 |
Hypotaurine / cysteine | Inverse variance weighted | 55.86 | 32 | 0.005 |
Retinol (Vitamin A) / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [2] | MR Egger | 42.15 | 22 | 0.006 |
Retinol (Vitamin A) / linoleoyl-arachidonoyl-glycerol (18:2 to 20:4) [2] | Inverse variance weighted | 43.13 | 23 | 0.006 |